Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: J Stone who wrote (22909)	7/3/1998 10:37:00 AM
From: jayhawk969	Read Replies (1) \| Respond to of 32384

<Given Ligand's current development stage, the probability of bad news is pretty minimal.> Ontack is not yet approved and failure to aprove will provide a hit to this stock. In addition Karposi's appears to be in significant decline. This decline in the incidence of Karposi may or may not reverse itself. This is a threat to the financial profitability of Ligands "not yet approved NDA" and I believe investors are responding negatively to this threat and the delay of Ontak. <Unless Panretin and Targretin are found to be toxic> "or not effective in human trials", <this stock is basically within 20% of its floor.> I believe that this stock continues to be, as others have said, event driven. We just need more bottom line events and pipeline milestones rather than just news events, which, tend to wear off quickly. Personaly I belive the best gamble is SRGN. It has been drifting lower. With Ontak's approval there is a .23 per share kicker within a reasonable time period. If Ontak's approval chance is above 90% this is a damn good wager.